We have located links that may give you full text access.
Outcomes of Dual Mobility Acetabular Cups in Total Hip Arthroplasty Patients.
Surgical Technology International 2018 November 31
BACKGROUND: Instability can account for over 20% of all revision total hip arthroplasties (THAs). Although a number of surgical techniques have been developed to limit the number of dislocations, prevention still remains a challenge. More recently, dual mobility (DM) cups have been developed to potentially target this problem. Although this implant design has been shown to have a number of potential advantages in the revision setting, there is limited data in the literature on the use of modular dual mobility (MDM) implants for primary THAs. Therefore, the purpose of this study was to evaluate cup survivorships, patient satisfaction outcomes, and complications of this device used for primary THA.
MATERIALS AND METHODS: A total of 143 consecutive hips (131 patients) who underwent primary THA using DM prostheses by a high-volume academic surgeon were longitudinally followed up for a minimum of five years (mean: 6 years, 11 months; range, 6 years 3 months to 7 years 5 months). There were 77 women (54%) and 66 men (44%) who had a mean age 65 years (range, 34 to 90 years; SD, 11 years), and the mean body mass index (BMI) was 32 kg/m2 (range, 22 to 52; SD, 8 kg/m2). Patient demographics, (gender, BMI), as well as clinical outcomes were analyzed. Kaplan-Meier analysis was performed to determine aseptic, septic, and all-cause cup survivorship. Additionally, clinical outcomes based on Harris Hip Scores (HHS) and other modalities, as well as complications, were tabulated. Institutional review board (IRB) approval was received prior to initiating this study.
RESULTS: Septic survivorship was found to be 99.3% (95% CI: 0.98 to 1.0), while all-cause survivorship was 98.6% (95% CI: 0.97 to 1.0). There were a total of two revision surgeries; however, these were not related to the MDM cup. Specifically, one patient had femoral stem loosening, while another patient had a late deep infection treated with a two-stage procedure. At most recent follow up, both patients were progressing well and had HHS scores of 85 and 92 points. The mean total HHS score was 95 points (range, 64 to 100) at most recent follow up. Other complications affecting patient outcomes included two patients who presented with concerns for deep vein thrombi, which were both medically managed, as well as one patient who had a non-fatal pulmonary embolism, which was also medically managed. The final HHS scores for these three patients were 83, 100, and 96 points.
CONCLUSION: DM cups were designed with the intent of reducing hip instability. Most studies on these cups have reported on revision THA, where the problem of instability may be more paramount; however, fewer studies have reported on the use of this cup for primary THA. The findings from this study indicate excellent survivorship and overall clinical and patient satisfaction results using this construct. These five-year results are very encouraging and hopefully will portend excellent further survivorship with longer follow up.
MATERIALS AND METHODS: A total of 143 consecutive hips (131 patients) who underwent primary THA using DM prostheses by a high-volume academic surgeon were longitudinally followed up for a minimum of five years (mean: 6 years, 11 months; range, 6 years 3 months to 7 years 5 months). There were 77 women (54%) and 66 men (44%) who had a mean age 65 years (range, 34 to 90 years; SD, 11 years), and the mean body mass index (BMI) was 32 kg/m2 (range, 22 to 52; SD, 8 kg/m2). Patient demographics, (gender, BMI), as well as clinical outcomes were analyzed. Kaplan-Meier analysis was performed to determine aseptic, septic, and all-cause cup survivorship. Additionally, clinical outcomes based on Harris Hip Scores (HHS) and other modalities, as well as complications, were tabulated. Institutional review board (IRB) approval was received prior to initiating this study.
RESULTS: Septic survivorship was found to be 99.3% (95% CI: 0.98 to 1.0), while all-cause survivorship was 98.6% (95% CI: 0.97 to 1.0). There were a total of two revision surgeries; however, these were not related to the MDM cup. Specifically, one patient had femoral stem loosening, while another patient had a late deep infection treated with a two-stage procedure. At most recent follow up, both patients were progressing well and had HHS scores of 85 and 92 points. The mean total HHS score was 95 points (range, 64 to 100) at most recent follow up. Other complications affecting patient outcomes included two patients who presented with concerns for deep vein thrombi, which were both medically managed, as well as one patient who had a non-fatal pulmonary embolism, which was also medically managed. The final HHS scores for these three patients were 83, 100, and 96 points.
CONCLUSION: DM cups were designed with the intent of reducing hip instability. Most studies on these cups have reported on revision THA, where the problem of instability may be more paramount; however, fewer studies have reported on the use of this cup for primary THA. The findings from this study indicate excellent survivorship and overall clinical and patient satisfaction results using this construct. These five-year results are very encouraging and hopefully will portend excellent further survivorship with longer follow up.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app